Warrants of series TO3 were subscribed to approximately 90.4 percent and Pharmacolog receives approximately SEK 2.3 million
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW.
Pharmacolog i Uppsala AB (publ) (”Pharmacolog” or the ”Company”) announces today the outcome of the exercise of warrants of series TO3, which were issued in connection with the Compan’’s rights issue of units on Nasdaq First North Growth Market which was completed in July 2023. In total, 42,269,834 warrants of series TO3 were exercised, corresponding to approximately 90.4 percent of the total number of outstanding warrants of series TO3, for subscription of 42,269,834 series B shares. Pharmacolog will receive approximately SEK 2.3 million before issue costs through the exercise of the warrants of series TO3.
Background
The exercise period for the warrants of series TO3 took place from February 9, 2024 up to and including February 23, 2024. The subscription price per share for exercising the warrants of series TO3 was set to SEK 0.054.
In total, 42,269,834 warrants of series TO3 were exercised for subscription of 42,269,834 series B shares, meaning that approximately 90.4 percent of all outstanding warrants of series TO3 were exercised for subscription of series B shares.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.
Number of shares, share capital and dilution
Through the exercise of the warrants of series TO3, the number of shares in Pharmacolog increases by 42,269,834 series B shares, from 66,250,342 to 108,520,176. The share capital will increase by SEK 422,698.34, from SEK 662,503.42 to SEK 1,085,201.76.
For existing shareholders who did not exercise any warrants of series TO3, the dilution amounts to approximately 39.0 percent based on the number of shares following exercise of the warrants of series TO3.
Advisors
Mangold Fondkommission AB is the financial advisor to Pharmacolog in connection with the exercise of the warrants. Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants.
This disclosure contains information that Pharmacolog is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-02-2024 11:38 CET.
For more information contact:
Lars Gusch, CEO
Email: lars.gusch@pharmacolog.com
Phone: +46 70-223 97 72
About Pharmacolog
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, WasteLog™and Pharmacolog Dashboard™.
Further information regarding the company is available at https://perpetuamedical.se/.
The company’s Certified Adviser is Mangold Fondkommission AB.
Important information
The publication, announcement, or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions under law, and individuals in jurisdictions where this press release has been published or distributed should inform themselves about and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each respective jurisdiction. This press release does not constitute an offer to, or an invitation to, acquire or subscribe for any securities in Pharmacolog in any jurisdiction, neither from Pharmacolog nor from any other party.
This press release does not constitute an offer to sell or an invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration or without applying an exemption from registration under the then-applicable U.S. Securities Act of 1933 (“Securities Act”), and may not be offered or sold in the United States without registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities mentioned herein in the United States or to conduct a public offering of such securities in the United States. The information in this press release may not be published, disclosed, copied, reproduced, or distributed, directly or indirectly, in whole or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, Russia, or any other jurisdiction where such publication, disclosure, or distribution of this information would be in violation of applicable rules or where such action is subject to legal restrictions or would require further registration or other measures than those required by Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities laws.